ArticleCardiorenal medicine2025
Global Burden and Health Inequalities of Heart Failure Attributable to Chronic Kidney Disease: A Comprehensive Analysis from 1990 to 2021.
Article in Cardiorenal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited data are available regarding the global burden of heart failure attributable to chronic kidney disease (CKD-HF). The aim of this study was to estimate the disease burden and cross-national disparities in CKD-HF from 1990 to 2021.
methodsCKD-HF prevalence and years lived with disability (YLDs) were extracted from the Global Burden of Disease (GBD) database. The slope index of inequality (SII) and concentration index were adopted for analyzing absolute and relative health inequalities, and the autoregressive integrated moving average (ARIMA) model was applied to project trends in CKD-HF burden through 2040.
resultsFrom 1990 to 2021, the CKD-HF age-standardized prevalence rate (ASPR) globally increased from 13.58 per 100,000 (95% uncertainty interval (UI): 11.16-16.22) to 24.21 (95% UI: 19.86-29.23), and the age-standardized years lived with disability (ASYR) increased from 1.73 (95% UI: 1.12-2.56) to 3.07 (95% UI: 1.95-4.44). By 2040, the global ASPR is projected to increase to 30.90 (95% confidence interval (CI): 29.62-32.18), with the ASYR expected to increase to 3.84 (95% CI: 3.59-4.08). In 2021, the highest ASPRs were observed in Western Sub-Saharan Africa, Andean Latin America and Central Latin America, whereas the highest ASYRs were observed in Australasia, Tropical Latin America, and Andean Latin America. Diabetic nephropathy and hypertensive nephropathy have emerged as increasingly significant drivers of the CKD-HF burden. The CKD-HF burden exhibited significant health inequities, with low-sociodemographic index (SDI) regions bearing a disproportionate share of the burden, a trend that is expected to persist through 2040.
conclusionPatients with CKD-HF exhibited a sustained increase in disease burden, a shift in the underlying cause distribution, and significant health disparities. There is an urgent need for more region-specific strategies to prevent the underlying causes and improve medical care for patients with CKD-HF to mitigate the future burden of this condition.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.